Breaking News, Collaborations & Alliances

CordenPharma Signs Multi-Year Agreement for the Manufacturing of a Commercial Peptide

The CDMO also plans to invest more than $200 million in 2023 in key areas such as peptides, lipids, and injectables.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma has signed a multi-year agreement starting in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility. The manufacturing agreement will potentially cover a value of $1 billion, depending on actual production over the term of the agreement, and will support the launch of an innovative peptide. The companies have agreed not to disclose additional details and respect customer confidentiality. “We are very excited about the trust our cus...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters